Sale!

HLA Cadaveric Crossmatch Test

Original price was: 2,420 د.إ.Current price is: 2,180 د.إ.

-10%

The HLA Cadaveric Crossmatch Test is a critical diagnostic procedure conducted to ensure compatibility between a donor’s organ and a recipient’s immune system before organ transplantation. This test focuses on the human leukocyte antigen (HLA) system, a group of genes that play a crucial role in the body’s immune response. By evaluating the interaction between the recipient’s serum and the donor’s HLA, the test aims to predict the likelihood of the recipient’s immune system rejecting the transplanted organ.

Performed at DNA Labs UAE, a facility known for its advanced diagnostic services and state-of-the-art technology, the HLA Cadaveric Crossmatch Test is a key step in the pre-transplantation process. Ensuring compatibility can significantly increase the success rate of organ transplants and improve the recipient’s prognosis.

The cost of the HLA Cadaveric Crossmatch Test at DNA Labs UAE is 2,180 AED. This price reflects the complex nature of the test and the sophisticated equipment and expertise required to accurately analyze HLA compatibility. For patients and their families, investing in this test is a critical part of the journey towards a successful organ transplant, offering hope and a chance for a healthier future.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

HLA CADAVERIC CROSSMATCH Test

At DNA Labs UAE, we offer the HLA cadaveric crossmatch test for organ transplantation, specifically for kidney transplants. This test helps determine the compatibility between the donor and recipient, reducing the risk of rejection and increasing the success rate of the transplant.

Test Cost: AED 2180.0

The HLA cadaveric crossmatch test is available at a cost of AED 2180.0.

Symptoms and Diagnosis

The HLA cadaveric crossmatch test is performed prior to organ transplantation to assess compatibility. During the test, the recipient’s serum is mixed with the donor’s lymphocytes. If the recipient’s antibodies react with the donor’s cells, it indicates a positive crossmatch, which suggests a high risk of rejection if the transplant proceeds. A negative crossmatch, on the other hand, indicates compatibility between the donor and recipient, reducing the risk of rejection.

Sample Condition

Recipient: 6 mL (3 mL min.) whole blood in 1 Yellow Top (ACD) tube AND 3 mL (2 mL min.) serum from 1 SST. Collect specimen preferably 48 hours after dialysis.

Cadaveric Donor: 12 mL (10 mL min.) whole blood in 2 Yellow Top (ACD) tubes. Ship refrigerated. DO NOT FREEZE.

Note: Doctor’s prescription on the letterhead with stamp and a photograph of the recipient is mandatory.

Report Delivery

The test results are typically delivered within 10-12 days.

Method

The HLA cadaveric crossmatch test is performed using the Complement Dependent Cytotoxicity with DTT treatment method.

Test Type

The HLA cadaveric crossmatch test falls under the category of transplantation tests.

Doctor

This test is typically requested by Nephrologists and Gastroenterologists.

Test Department

This test is conducted in the Transplantation department.

Pre Test Information

It is recommended to collect the specimen 48 hours after dialysis. Additionally, a doctor’s prescription on the letterhead with a stamp and a photograph of the recipient is mandatory.

Test Details

The HLA (human leukocyte antigen) cadaveric crossmatch test is a crucial laboratory test performed before organ transplantation, specifically for kidney transplants. It helps determine the compatibility between the donor and recipient. By mixing the recipient’s serum with the donor’s lymphocytes, the test identifies if the recipient’s antibodies react with the donor’s cells. A positive crossmatch indicates a high risk of rejection, usually due to pre-formed antibodies in the recipient’s blood resulting from previous transplants, blood transfusions, or pregnancies. In such cases, the transplant is typically contraindicated. Conversely, a negative crossmatch indicates compatibility, reducing the risk of rejection and allowing the transplant to proceed with a lower risk of complications.

Overall, the HLA cadaveric crossmatch test plays a crucial role in ensuring the success and long-term viability of organ transplantation by assessing the compatibility between the donor and recipient.

Test Name HLA CADAVERIC CROSSMATCH Test
Components
Price 2180.0 AED
Sample Condition RECIPIENT: 6 mL (3 mL min.) whole blood in 1 Yellow Top (ACD) tube AND 3 mL (2 mL min.) serum from 1 SST. Collect specimen preferably 48 hours after dialysis.\nCADAVERIC DONOR: 12 mL (10 mL min.) whole blood in 2 Yellow Top (ACD) tubes. Ship refrigerated. DO NOT FREEZE. Doctor’s prescription on the letter head with stamp ANDphotograph of recipientis mandatory. Above specimen requirements are for a single donor being cross matched with a single recipient. For additional cross matches, send additional specimens of recipients. Request as additional tests.
Report Delivery 10-12 days
Method Complement Dependent Cytotoxicity with DTT treatment
Test type Transplantation
Doctor Nephrologist, Gastroenterologist
Test Department:
Pre Test Information Collect specimen preferably 48 hours after dialysis. Doctor’s prescription on the letter head with stamp ANDphotograph of recipientis mandatory.
Test Details

The HLA (human leukocyte antigen) cadaveric crossmatch test is a laboratory test performed prior to organ transplantation, specifically for kidney transplants. It is used to determine if there is compatibility between the donor and recipient.

During the test, the recipient’s serum (the liquid part of blood) is mixed with the donor’s lymphocytes (white blood cells). If the recipient’s antibodies react with the donor’s cells, it indicates a positive crossmatch, meaning there is a high risk of rejection if the transplant proceeds.

A positive crossmatch result may occur due to the presence of pre-formed antibodies in the recipient’s blood, which can be a result of previous transplants, blood transfusions, or pregnancies. In such cases, the transplant is usually contraindicated.

On the other hand, a negative crossmatch indicates compatibility between the donor and recipient, reducing the risk of rejection. This allows the transplant to proceed with a lower risk of complications.

Overall, the HLA cadaveric crossmatch test plays a crucial role in ensuring the success and long-term viability of organ transplantation by assessing the compatibility between the donor and recipient.